More on GLUE

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.2 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Monte Rosa Therapeutics (NQ:GLUE)
Delayed: 10.84 -0.27 (2.43%)
Prev. Close $11.11  
Open$11.03 
52 Wk High$ 
52 Wk Low$ 
Day High$11.03 
Day Low$10.61 
P/E N/A  
EPS$ 
Volume817,827 

Friends, Peers and Foes (?): ALNY, ARVN, ARWR, CAPR, CRSP (more...)

Oct 12, 2026 08:52 AM Monte Rosa Therapeutics (GLUE) PT Raised to $19 at UBS
Oct 6, 2026 04:05 PM Form 4 Monte Rosa Therapeutics, For: Oct 05 Filed by: Bowen Matthew
Oct 5, 2026 06:43 AM H.C. Wainwright Reiterates Buy Rating on Monte Rosa Therapeutics (GLUE)
Oct 2, 2026 04:01 PM Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2026 07:38 AM Form 8-K Monte Rosa Therapeutics, For: Oct 01
Oct 1, 2026 07:00 AM Monte Rosa reports Phase 1 data for MRT-8102 in cardiovascular study
Oct 1, 2026 07:00 AM Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Oct 1, 2026 06:07 AM H.C. Wainwright Starts Monte Rosa Therapeutics (GLUE) at Buy
Sep 30, 2026 04:01 PM Monte Rosa to share Phase 1 MRT-8102 cardiovascular study data
Sep 30, 2026 04:01 PM Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
View All Articles

Entities mentioned with GLUE

View All Entities